Overview

• The Council of Ministers adopted a Royal Decree that integrates standardized cannabis-based magistral formulas into the national health system.
• Officials cite scientific evidence of benefit for multiple sclerosis–related spasticity, certain severe refractory epilepsies, chemotherapy‑induced nausea and vomiting, and refractory chronic pain.
• Prescribing is limited to hospital specialists, and preparation and dispensing will occur only in authorized hospital pharmacy services with shared clinical follow‑up.
• A public registry managed by AEMPS and strict requirements for manufacturing, traceability, and defined THC/CBD composition are established, with additional controls for products exceeding 0.2% THC.
• The General Council of Pharmacists criticizes the hospital‑only model and calls for community pharmacy dispensing, while regions may allow exceptional non‑in‑person delivery for vulnerable or geographically isolated patients.